SOURCE: Crucell N.V.

September 14, 2007 06:04 ET

Crucell to present pre-clinical results for H5N1 Virus treatment

LEIDEN, NETHERLANDS--(Marketwire - September 14, 2007) -

Leiden, The Netherlands, September 14, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that its researchers have discovered a monoclonal antibody that is active against H5N1 avian influenza. The studies will be presented at the 5th International Bird Flu Summit scheduled for September 27 and 28 in Las Vegas, Nevada.

Crucell researchers produced antibodies in PERC6® cells and tested their biophysical and immunological properties.

"Using phage display technology a set of human monoclonal antibodies active against a broad range of distinct H5N1 strains was developed," said Crucell Chief Scientific Officer Dr. Jaap Goudsmit. "We will show the ability of these antibodies to prevent infection as well as to prevent and cure disease caused by H5N1 virus in mice."

Crucell will provide more information about the research findings during the two-day conference in Las Vegas.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Media:                            Investors/Analysts:

Barbara Mulder                    Oya Yavuz
Director Corporate Communications Director Investor Relations
Tel: 31-(0) 71 519 7346           Tel. +31-(0) 71-519 7064                

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information